Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 17/20 | 0.80 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.80 |
| ▸ | F2 | P00734 | 1/20 | 0.80 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Betrixaban SCHEMBL158591 | 0.89 | F10 (1.00) | F10KCNH2F2 | |
| Betrixaban SCHEMBL29374026 | 0.89 | F10 (1.00) | F10KCNH2F2 | |
| SCHEMBL19681318 | 0.88 | F10 (0.76) | F10KCNH2F2KLKB1 | |
| SCHEMBL12132941 | 0.88 | F10 (0.78) | F10KCNH2F2KLKB1 | |
| SCHEMBL14996400 | 0.88 | F10 (0.78) | F10KCNH2F2KLKB1 | |
| Betrixaban SCHEMBL29858125 | 0.88 | F10 (0.98) | F10KCNH2F2 | |
| SCHEMBL19128914 | 0.86 | F10 (0.73) | F10KCNH2F2KLKB1 | |
| SCHEMBL6109439 | 0.86 | F10 (0.75) | F10KCNH2F2KLKB1 | |
| SCHEMBL19414031 | 0.86 | F10 (0.82) | F10KCNH2F2KLKB1 | |
| SCHEMBL2434887 | 0.85 | F10 (0.75) | F10KCNH2F2KLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180028510-A1 | PREVENTION AND TREATMENT OF THROMBOSIS IN MEDICALLY ILL PATIENTS | ALEXION PHARMACEUTICALS, INC. | 2018-02-01 | — | — | US | disclosed |
| US-20150224091-A1 | PREVENTION AND TREATMENT OF THROMBOSIS IN MEDICALLY ILL PATIENTS | PORTOLA PHARMACEUTICALS, INC. | 2015-08-13 | — | — | US | disclosed |
| US-20140323497-A1 | METHODS AND FORMULATIONS OF TREATING THROMBOSIS WITH BETRIXABAN AND A P-GLYCOPROTEIN INHIBITOR | PORTOLA PHARMACEUTICALS, INC. (US) | 2014-10-30 | — | — | US | disclosed |
| US-8455440-B2 | Combination anticoagulant therapy with a compound that acts as a factor Xa inhibitor | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| US-20120095019-A1 | METHODS AND FORMULATIONS OF TREATING THROMBOSIS WITH BETRIXABAN AND A P-GLYCOPROTEIN INHIBITOR | ALEXION PHARMACEUTICALS, INC. | 2012-04-19 | — | — | US | disclosed |
| US-20120046230-A1 | Combination Anticoagulant Therapy With A Compound That Acts As A Factor Xa Inhibitor | MILLENNIUM PHARMACEUTICALS, INC. | 2012-02-23 | — | — | US | disclosed |
| US-20080254036-A1 | COMBINATION ANTICOAGULANT THERAPY WITH A COMPOUND THAT ACTS AS A FACTOR XA INHIBITOR | MILLENNIUM PHARMACEUTICALS, INC. | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150224091-A1 | PREVENTION AND TREATMENT OF THROMBOSIS IN MEDICALLY ILL PATIENTS | SERPINC1, TBXA2R, PLAT | F10 37/4885KCNH2 2677/4885F2 12/4885 |
| US-20120046230-A1 | Combination Anticoagulant Therapy With A Compound That Acts As A Factor Xa Inhibitor | SERPINC1, F2, TFPI | F10 6/4885KCNH2 1976/4885F2 2/4885 |
| US-20140323497-A1 | METHODS AND FORMULATIONS OF TREATING THROMBOSIS WITH BETRIXABAN AND A P-GLYCOPROTEIN INHIBITOR | ABCB1, PLAT, TFPI | F10 32/4885KCNH2 728/4885F2 31/4885 |
| US-20120095019-A1 | METHODS AND FORMULATIONS OF TREATING THROMBOSIS WITH BETRIXABAN AND A P-GLYCOPROTEIN INHIBITOR | ABCB1, PLAT, TFPI | F10 32/4885KCNH2 728/4885F2 31/4885 |
| US-20180028510-A1 | PREVENTION AND TREATMENT OF THROMBOSIS IN MEDICALLY ILL PATIENTS | SERPINC1, TBXA2R, PLAT | F10 37/4885KCNH2 2677/4885F2 12/4885 |
| US-20080254036-A1 | COMBINATION ANTICOAGULANT THERAPY WITH A COMPOUND THAT ACTS AS A FACTOR XA INHIBITOR | SERPINC1, F2, TFPI | F10 6/4885KCNH2 1976/4885F2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.